Categories
BLOG

psychedelic marijuana

‘A tipping point’: Psychedelics, cannabis win big across the country on election night

As the nation awaits a final result from the presidential election, a clear winner emerged Tuesday: drugs.

Measures to legalize cannabis and decriminalize other drugs won major victories this week as five states — Arizona, New Jersey, South Dakota, Montana and Mississippi — legalized some form of marijuana use and Oregon became the first state to make possession of small amounts of harder drugs, including cocaine, heroin and methamphetamine, violations not punishable by jail time.

Voters in Oregon and Washington, D.C., also approved measures to allow for the therapeutic use of psychedelic mushrooms, which are already being prescribed to help some terminally ill patients in Canada cope with pain and end-of-life anxiety.

“People are realizing it’s not just about getting high,” said Avis Bulbulyan, CEO of SIVA Enterprises, a cannabis business development and solutions firm based in Glendale, California, near Los Angeles. “This is a tipping point for drug policy absent any federal reform.”

On Tuesday, South Dakota became the first state whose voters approved both recreational and medical cannabis in the same election. Medicinal marijuana also was made legal in Mississippi. Meanwhile, New Jersey, Montana and Arizona all legalized recreational cannabis.

“Despite this public consensus, elected officials have far too often remained unresponsive to the legalization issue,” Erik Altieri, executive director of the National Organization for the Reform of Marijuana Laws, or NORML, said in a statement.

NORML has lobbied for the end of marijuana prohibitions since it was founded in 1970.

“These results once again illustrate that support for legalization extends across geographic and demographic lines,” Altieri said. “The success of these initiatives proves definitively that marijuana legalization is not exclusively a ‘blue’ state issue, but an issue that is supported by a majority of all Americans — regardless of party politics.”

Download the NBC News app for breaking news and politics

Just 10 years ago, recreational cannabis was illegal in all 50 states, but that started to change in 2012, when Colorado and Washington became the first states to legalize marijuana for recreational use. At the time, California, which has one of the biggest and oldest marijuana markets in the country, allowed only medicinal use of cannabis.

A domino effect followed, with several more states venturing into the medicinal markets, including Pennsylvania in 2016 and New York in 2014. Now, 15 states, two territories and Washington, D.C., have legalized marijuana for recreational use, while 34 states and two territories allow medical marijuana.

Related

News MAP: See the states where marijuana is legal

“It’s fantastic to see this cannabis sweep,” said Stuart Titus, CEO of Medical Marijuana Inc., a hemp products company based in San Diego. “There is a tremendous momentum building. I think we’re right on the precipice of changing federal policy with so many states coming online.”

Despite the ballot initiatives, marijuana and other drugs remain illegal at the federal level. The Drug Enforcement Administration continues to classify cannabis as a Schedule 1 drug akin to LSD, heroin and ecstasy.

In New Jersey, some advocates for cannabis legalization worry that the state ballot measure remains too murky and would not tackle social justice concerns surrounding the so-called war on drugs.

The question posed to voters appears simple at first glance: “Do you approve amending the Constitution to legalize a controlled form of marijuana called ‘cannabis’?”

While the majority of voters said yes, the language would not necessarily decriminalize all adult-use cannabis. Instead, it would make only “a controlled form” of the plant legal, said Chris Goldstein, a regional organizer for NORML.

“New Jersey voters sent a message to the Legislature — they want prohibition to end,” he said. “They want people to stop getting arrested.”

The Legislature will now have to pass another measure to set up the new cannabis marketplace. Whether that will reduce marijuana arrests and convictions remains to be seen, Goldstein said.

Meanwhile, Arizona’s measure allows people convicted of certain cannabis crimes to seek expungement of their records. Arizona voters narrowly defeated a legal pot proposal in 2016.

Cannabis was not the only drug on the ballot.

In Oregon, voters approved Measure 110 to allow a person found in possession of small amounts of hard drugs to avoid jail time by paying a $100 fine or attending an addiction recovery center. The centers would be funded through tax revenue collected from the state’s legal cannabis program.

Separately, Oregon voters passed measures to decriminalize psychedelic drugs, as did voters in Washington, D.C.

In Washington, D.C., Initiative 81 will lower the enforcement priority for “entheogenic plants and fungi,” or psychedelic mushrooms and mescaline-containing cacti. The ballot measure would not legalize psychedelics in the nation’s capital.

Oregon, however, became the first state to legalize psilocybin, also called magic mushrooms.

Measure 109 calls for the manufacture and therapeutic use of psilocybin to treat patients with mental health disorders. Some research suggests that psilocybin, when ingested in small doses under supervised settings, can ease stress and induce feelings of happiness.

In one recent study, patients who were given a single dose of the psychedelic drug to ease depression and anxiety still felt its positive effects years later. The patients were given small amounts of psilocybin in 2016 to look at whether it could ease cancer-related anxiety and depression. Eighty percent of the patients said their symptoms faded.

“What is permanent is that I don’t have anxiety about cancer. Not only about my cancer returning, but how I viewed my reoccurrence when it did happen,” Dinah Bazer, who was diagnosed in March with a type of rare gastrointestinal cancer, said at the time.

Alicia Victoria Lozano is a Los Angeles-based digital reporter for NBC News.

'A tipping point': Psychedelics, cannabis and even harder drugs win big across the country on election night with voter-approved ballot measures in five states and D.C.

Medical Marijuana

MAPS has completed the first-ever clinical trial of smoked marijuana for symptoms of posttraumatic stress disorder (PTSD) in veterans of war.

MAPS is working to demonstrate the safety and efficacy of smoked botanical marijuana as a prescription medicine for specific medical uses to the satisfaction of the U.S. Food and Drug Administration.

Our efforts to initiate medical marijuana research have been hindered by the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA) since our founding in 1986. NIDA’s previous monopoly on the supply of marijuana for research and the DEA’s prior refusal to allow researchers to grow their own has restricted medical marijuana research for decades. Since 1999, MAPS was involved in legal struggles against the DEA to end this situation. On August 11, 2016, the DEA announced their intention to grant licenses to additional marijuana growers for research, thereby ending the DEA-imposed 48-year monopoly on federally legal marijuana.

On March 14, 2014, the U.S. Public Health Service approved our study of smoked whole plant (botanical) marijuana for symptoms of PTSD in U.S. veterans. MAPS worked for over 22 years to obtain marijuana for medical marijuana drug development research, and the approval is a historic shift in federal policy. On December 17, 2014, MAPS was awarded a $2 million grant from the Colorado Department of Public Health and Environment to complete the study. The study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs). The study began in January 2017 at Scottsdale Research Institute in Phoenix, Arizona, and completed its treatment phase in January 2019. We anticipate that the resulting paper will be submitted to journals for publication by June 2019.

See below for frequently updated information about completed, ongoing, or planned MAPS studies.

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.MAPS furthers its mission by: Developing psychedelics and marijuana into prescription medicines; Training therapists and working to establish a network of treatment centers; Supporting scientific research into spirituality, creativity, and neuroscience; and educating the public honestly about the risks and benefits of psychedelics and marijuana.